
Peloton pivots to wellness alongside another layoff
'With each passing year, we are coming to understand better the importance of strength, stress management, sleep, and nutrition to living our best lives,' CEO Peter Stern said during the call. 'This creates the opportunity, no more than that, the mandate, for Peloton to evolve from being a cardio fitness partner to becoming the world's most trusted wellness partner across the full array of behaviors that maximize health demand.'
He went on the explain that the company will focus on 'health span', or the period of life a person lives in good health. 'Advances in medical science contributed to the prolonging of life here in the US by a remarkable 40 years from 1900 to 2020,' Stern says. 'However, as life span has increased, health span, the quality as opposed to quantity, of those years has failed to keep up. People are living longer but they're also living sicker in the U.S.'
Health span isn't a new concept. Whoop also just released a Health Span feature with its latest tracker earlier this summer. Peloton's take on improving wellness will reportedly involve investing more in its personalized training programs, the standalone Strength Plus app, as well as meditation and sleep features. Stern also said that Peloton would test and iterate on bringing nutritional content to its platform. In a shareholder letter, Stern highlighted using AI and integrating with health tracking devices as a means to provide 'increasingly personal insights, plans, and recommendations' to its members.
On the business side, Peloton exceeded investor expectations in all metrics. It posted $607 million in revenue, roughly $21 million above the top end of its expected guidance range. Connected paid fitness subscriptions and paid app subscriptions also exceeded targets, posting 2.8 million and 552,000, respectively. Peloton shares rose roughly 11 percent on the news, but Stern noted that the company's operating expenses were still too high.
As a result, Stern says the company will undergo another cost restructuring plan that includes laying off about six percent of its workforce. 'This is not a decision we came to lightly, as it impacts many talented team members, but we believe it is necessary for the long-term health of our business,' Stern writes in the shareholder letter. This marks the company's sixth round of layoffs, coming a little over a year after the company laid off 15 percent of its workforce and former CEO Barry McCarthy stepped down.
Peloton also plans to adjust pricing. That includes a new assembly fee for its hardware, which was previously free with purchase. (There will still be a free option for self-assembly.) The company also plans to introduce a new Special Pricing program to make its products more affordable for teachers, military personnel, first responders, and medical professionals.
Posts from this author will be added to your daily email digest and your homepage feed.
See All by Victoria Song
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Business
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Fitness
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Gadgets
Posts from this topic will be added to your daily email digest and your homepage feed.
See All News
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Wearable

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Primo Brands Second Quarter 2025 Earnings: Misses Expectations
Explore Primo Brands's Fair Values from the Community and select yours Primo Brands (NYSE:PRMB) Second Quarter 2025 Results Key Financial Results Revenue: US$1.73b (up 32% from 2Q 2024). Net income: US$30.5m (down 44% from 2Q 2024). Profit margin: 1.8% (down from 4.1% in 2Q 2024). EPS: US$0.081 (down from US$52.89 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Primo Brands Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) also missed analyst estimates by 83%. Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Beverage industry in the US. Performance of the American Beverage industry. The company's shares are down 12% from a week ago. Risk Analysis We should say that we've discovered 2 warning signs for Primo Brands (1 shouldn't be ignored!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
At 207%, the Warren Buffett indicator says the stock market could crash!
Billionaire investor Warren Buffett has shared a lot of wisdom throughout his successful career. However, one gem to come off his desk is the Buffett Indicator – a simple comparison of the US stock market's total value divided by US GDP. As Buffett puts it, the indicator is 'probably the best single measure of where valuations stand at any given moment'. And for value investors, knowing when the stock market is overpriced is a powerful advantage, even when relying only on index funds. However, looking at the Buffett Indicator today might cause some concern. US stocks are expensive Historically, his Indicator has sat between 90% and 135%. This healthy range generally indicates that US stocks are fairly-to-slightly overvalued and presents an ideal window of opportunity to top up on investments. But following the tremendous artificial intelligence (AI)-driven returns of 2023 and 2024, the indicator's been rising. So much so that it now sits at a whopping 207%! That's the highest it's ever been since records began in the 1970s. And it's even higher than the 194% peak seen in late 2021, right before US stocks experienced one of the most severe market corrections seen in over a decade. That would certainly explain why Buffett and his team at investment vehicle Berkshire Hathaway have been busy selling stocks lately. In fact, the firm just marked its 11th consecutive quarter of being a net seller, with positions such as Bank of America, Citigroup, and Capital One all getting trimmed, or outright sold off. So could another stock market downturn be just around the corner? Panic isn't a strategy The stretched valuation of US stocks definitely creates cause for concern. However, there's no guarantee a crash or correction will actually materialise. Therefore, panic selling everything today likely isn't a sensible strategy, and it's why Buffett, despite higher selling activity, still has plenty of capital invested in the US stock market. In fact, he recently added $549m of Domino's Pizza (NASDAQ:DPZ) to its investment portfolio. His investment thesis is relatively simple. As the world's largest pizza delivery company, Domino's runs a 99% franchised business model. Combining this with its recurring ingredient & supply chain revenue and its high-margin royalty income, the business is highly cash generative. And what's more, the firm's proven to be quite recession-resistant since people tend to eat pizza during both the good times and the bad. Of course, Buffett still highlighted some notable risks. Rising labour and ingredient prices do put pressure on profit margins, and the general shift towards healthier dining could erode demand over time. Nevertheless, he sees ample long-term potential for steady gains here. And given his track record of success, investors may want to take a closer look. Will the stock market crash in 2025? There's no way of knowing whether the stock market will take a nosedive later this year. Even with the Buffett Indicator at sky-high levels, Berkshire's investment in Domino's suggests there are still bargains to be found among US stocks. Therefore, investors could be well served to follow in Buffett's footsteps, not by panic-selling, but by trimming overvalued positions to maintain portfolio diversification and hunting for hidden bargains. The post At 207%, the Warren Buffett indicator says the stock market could crash! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Gilead's Yeztugo sales 'ahead of expectations' following launch
After Gilead Sciences was given the green light for Yeztugo (lenacapavir) in the US and Europe, CCO Johanna Mercier said it is 'well ahead of expectations' in a Q2 investor call. The twice-yearly pre-exposure prophylaxis (PrEP) therapy has made headlines for its capacity to prevent 100% of HIV cases in a trial involving South African and Ugandan women – resulting in the jab's approval in June. While Gilead did not reveal how much the flagship drug has made for the company thus far, Mercier noted that unaided awareness on Yeztugo was 'at about 72%,' which is 'more than double that you'd see in industry at launch'. Looking forward, GlobalData, parent company of Pharmaceutical Technology, has forecasted that the star HIV drug will bring in just under $5bn in 2031, making it one of the company's most lucrative assets. However, some analysts had concerns about the drug's future uptake following the Supreme Court's ruling to allow Robert F. Kennedy Jr. (RFK Jr.) free rein over the US Preventive Services Task Force's (USPSTF) staffing and decision-making. Though the USPSTF currently recommends the use of Yeztugo as a preventive therapy for HIV, analysts feared that the division's restructure or complete overhaul could impact guidelines around the PrEP's usage, though Mercier believes that Gilead could 'work through it' by collaborating closely with its payers if this were to occur. The World Health Organisation (WHO) also recently announced new guidelines, which shift the agency's focus to preventive treatments, while prioritising the lowering of barriers to patient care for HIV management. Gilead has pledged to allow affordable Yeztugo in low-and middle-income countries after UNAIDS' executive director, Winnie Byanyima, called upon Gilead to allow for the immediate production of Yeztugo generics, as the drug's $40k US price tag could leave many in lower-income countries unable to afford treatment. HIV portfolio drives Gilead's overall growth On top of the early-stage success enjoyed by Yeztugo, Gilead has reported positive results for its HIV portfolio as a whole, with sales in this indication totalling $4.15bn this quarter. Blockbuster antiretroviral Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) also had 'one of its best quarters ever,' with sales jumping 9% to $3.5bn – constituting nearly half of the pharma's overall profits in the second quarter. Though the drug's patent is set to expire in October 2027, GlobalData's infectious disease analyst Anaelle Tannen noted that no HIV therapy is likely to be superior to Biktarvy in terms of commercial success. This is supported by GlobalData's forecast of a sales drop for Biktarvy's main competitor Dovato (dolutegravir and lamivudine), produced by ViiV Healthcare, which GlobalData forecasts will drop from $3.4bn in 2027 to $1.6bn in 2031, in part due to patents likely being made available in 2031. Though the HIV market is highly lucrative, with GlobalData predicting the HIV market will surpass $32bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). There are more than 40 drugs now approved for use in the indication, meaning pharma companies will have to differentiate themselves substantially to get a slice of this crowded market. One way companies are trying to differentiate is through the development of an HIV vaccine. While none have yet shown great promise, with two trials by Scripps Research, IAVI and additional collaborators across the US and Africa showing proof of concept at Phase I. "Gilead's Yeztugo sales 'ahead of expectations' following launch" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data